Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SHOP APOTHEKE EUROPE N.V.

(SAE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PRESS RELEASE : SHOP APOTHEKE EUROPE: Strong growth of everything-but-Rx.

10/05/2021 | 02:01am EST

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): 9 Month figures SHOP APOTHEKE EUROPE: Strong growth of everything-but-Rx. 2021-10-05 / 08:00 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

SHOP APOTHEKE EUROPE: Strong growth of everything-but-Rx. . Everything but Rx grew by 21.6% in the first nine months of 2021. . Preliminary total sales growth stands at 9.8% for the first nine months of 2021 to EUR 772 million, ontrack for full-year sales growth guidance. . A negative start of Q3 due to capacity constraints was offset by recovered growth towards the end of thequarter; Q3 growth -0.3%. . Number of active customers up 1 million in the first nine months of 2021 to 7.3 million (year-over-yearup 1.4 million). Sevenum, 5 October 2021. SHOP APOTHEKE EUROPE N.V., currently active in seven European countries, has increased sales for the first nine months of 2021 by 9.8% to EUR 772 million, according to preliminary calculations. Sales had been impacted by capacity constraints from May to mid-September, which resulted in preliminary Q3 sales growth of -0.3% to EUR 238 million. The number of active customers increased by 0.2 million to 7.3 million at the end of Q3.

CEO Stefan Feltens: "The move to our new next generation logistics centre was completed by the beginning of September. Our capacity constraints have been resolved. We no longer have a shortage of logistics personnel. This allows us to return to our growth trajectory and to be prepared for further growth in Q4 and 2022. Year to date, we are posting 9.8% growth thanks to continuously strong growth in our non-Rx assortment in our markets across Europe including Germany, which balanced a decrease of 30.6% in Rx sales in 2021 following the end of the Rx bonus in December 2020. We expect the launch of electronic prescriptions (e-Rx) in Germany soon."

In the DACH segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE's Q3 sales were EUR 189 million compared to the previous year's 201 million. 9M sales increased by 4.5% to EUR 618 million after EUR 592 million in 2020. 9M growth of non-Rx stands at 17.4%.

In the International segment (Belgium, France, Italy, the Netherlands), SHOP APOTHEKE EUROPE increased its sales in the third quarter of 2021 by 27.2% to EUR 48 million. 9M sales increased by 37.9% to EUR 154 million after EUR 112 million in 2020.

For the full year 2021, the Management Board of SHOP APOTHEKE EUROPE expects sales growth between 10 and 15% and an adjusted EBITDA margin around break-even.

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release its 9M interim report 2021 on 2 November 2021. Definitions of non-IFRS terms can be found in the Glossary of the Annual Report 2020 (pages 146 and 147).

ABOUT SHOP APOTHEKE EUROPE. SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Paris and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 7 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.

-----------------------------------------------------------------------------------------------------------------------

2021-10-05 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      SHOP APOTHEKE EUROPE N.V. 
              Dirk Hartogweg 14 
              5928 LV Venlo 
              Netherlands 
Phone:        0800 - 200 800 300 
Fax:          0800 - 90 70 90 20 
E-mail:       carmen.herkenrath@shop-apotheke.com 
Internet:     www.shop-apotheke-europe.com 
ISIN:         NL0012044747, DE000A19Y072 
WKN:          A2AR94, A19Y07 
Indices:      MDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1238180 
 
End of News   DGAP News Service 
=------------ 

1238180 2021-10-05

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1238180&application_name=news

(END) Dow Jones Newswires

October 05, 2021 02:00 ET (06:00 GMT)

All news about SHOP APOTHEKE EUROPE N.V.
11/25SHOP APOTHEKE EUROPE NV : Kepler Cheuvreux gives a Sell rating
MD
11/25SHOP APOTHEKE EUROPE NV : Jefferies gives a Buy rating
MD
11/19SHOP APOTHEKE EUROPE NV : Kepler Cheuvreux reiterates its Sell rating
MD
11/03Transkript Earnings Call Q3 2021 (Englisch)
PU
11/03SHOP APOTHEKE EUROPE NV : Hauck & Aufhauser reiterates its Neutral rating
MD
11/03SHOP APOTHEKE EUROPE NV : Deutsche Bank gives a Buy rating
MD
11/03SHOP APOTHEKE EUROPE NV : Receives a Buy rating from Warburg Research
MD
11/03SHOP APOTHEKE EUROPE NV : Berenberg reaffirms its Buy rating
MD
11/02SHOP APOTHEKE EUROPE NV : Jefferies maintains a Buy rating
MD
11/02GLOBAL MARKETS LIVE : Alphabet, Apple, DuPont de Nemours, Credit Suisse, Sika...
More news
Analyst Recommendations on SHOP APOTHEKE EUROPE N.V.
More recommendations
Financials
Sales 2021 1 069 M 1 211 M 1 211 M
Net income 2021 -47,2 M -53,5 M -53,5 M
Net Debt 2021 34,0 M 38,5 M 38,5 M
P/E ratio 2021 -61,5x
Yield 2021 -
Capitalization 2 922 M 3 307 M 3 308 M
EV / Sales 2021 2,76x
EV / Sales 2022 2,15x
Nbr of Employees 1 211
Free-Float 97,8%
Chart SHOP APOTHEKE EUROPE N.V.
Duration : Period :
Shop Apotheke Europe N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOP APOTHEKE EUROPE N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 161,50 €
Average target price 181,00 €
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Stefan Feltens Chief Executive Officer
Jasper Eenhorst Chief Financial Officer
Bj÷rn H. S÷der Chairman-Supervisory Board
Marc Fischer Chief Information Officer
Theresa Holler Chief Operating Officer
Sector and Competitors